Predilife (ALPRE) - Total Assets
Based on the latest financial reports, Predilife (ALPRE) holds total assets worth €1.31 Million EUR (≈ $1.53 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore ALPRE operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
Predilife - Total Assets Trend (2016–2024)
This chart illustrates how Predilife's total assets have evolved over time, based on quarterly financial data. See ALPRE book value for net asset value and shareholders' equity analysis.
Predilife - Asset Composition Analysis
Current Asset Composition (December 2024)
Predilife's total assets of €1.31 Million consist of 81.3% current assets and 18.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €350.50K | 43.3% |
| Accounts Receivable | €442.48K | 18.1% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €26.10K | 1.1% |
| Intangible Assets | €0.00 | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Predilife's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Predilife (ALPRE) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Predilife's current assets represent 81.3% of total assets in 2024, a decrease from 95.3% in 2016.
- Cash Position: Cash and equivalents constituted 43.3% of total assets in 2024, down from 70.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 18.1% of total assets.
Predilife Competitors by Total Assets
Key competitors of Predilife based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Predilife - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.45 | 1.60 | 3.96 |
| Quick Ratio | 0.45 | 1.60 | 3.96 |
| Cash Ratio | 0.08 | 0.30 | 0.08 |
| Working Capital | €-1.50 Million | €861.37K | €1.53 Million |
Predilife - Advanced Valuation Insights
This section examines the relationship between Predilife's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 35.76 |
| Latest Market Cap to Assets Ratio | 2.25 |
| Asset Growth Rate (YoY) | -72.3% |
| Total Assets | €2.44 Million |
| Market Capitalization | $5.50 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Predilife's assets at a significant premium (2.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Predilife's assets decreased by 72.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Predilife (2016–2024)
The table below shows the annual total assets of Predilife from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €2.44 Million ≈ $2.86 Million |
-72.29% |
| 2023-12-31 | €8.82 Million ≈ $10.31 Million |
+85.78% |
| 2022-12-31 | €4.75 Million ≈ $5.55 Million |
+19.71% |
| 2021-12-31 | €3.97 Million ≈ $4.64 Million |
-3.21% |
| 2020-12-31 | €4.10 Million ≈ $4.79 Million |
+203.51% |
| 2019-12-31 | €1.35 Million ≈ $1.58 Million |
-41.47% |
| 2018-12-31 | €2.31 Million ≈ $2.70 Million |
+128.71% |
| 2017-12-31 | €1.01 Million ≈ $1.18 Million |
-59.28% |
| 2016-12-31 | €2.48 Million ≈ $2.89 Million |
-- |
About Predilife
Predilife S.A. designs and markets predictive tests for the occurrence of serious illnesses. The company provides breast cancer predictive assessment; multi-pathology predictive assessment; and the Care4Eat solution, a nutrition assessment that allows employees to take stock of their eating habits and benefit from rebalancing and personalized advice. It also offers MammoRisk, a breast cancer pred… Read more